Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 3159 Download: 118 Web of Science: 1 Crossref: 1

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 4288 Download: 221 Web of Science: 7 Crossref: 12

Original Article

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function

Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique

Clin Mol Hepatol. 2017;23(4):316-322. Published online August 22, 2017

DOI: https://doi.org/10.3350/cmh.2016.0087

View: 8024 Download: 191 Web of Science: 12 Crossref: 16

Correspondence

Correspondence to editorials on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Woo Hyun Paik, Do Hyun Park

Received November 4, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0989 [Accepted]

View: 271 Download: 16

1 |

Viewed By 6195	MAFLD: How is it different from NAFLD?
Viewed By 5279	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5005	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4169	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3943	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search